Sarcopenia Pathogenesis and Emerging Treatments: A 2025 Deep Dive

Sarcopenia — first formally described in 1997 — is now recognized as a major global health threat, particularly as populations age. This 2025 narrative review from researchers at Guangdong Medical University provides one of the most thorough recent syntheses of sarcopenia's pathogenesis and therapeutic landscape, drawing on peer-reviewed clinical trials, meta-analyses, and mechanistic studies published between 2015 and 2023 across PubMed, Web of Science, and Cochrane Library.

Epidemiologically, sarcopenia affects roughly 5–10% of the general population, surging to 10–27% in adults over 60. Rates reach as high as 51% in male nursing home residents and 40.7% in liver transplant recipients, underscoring disease burden in vulnerable groups. Diagnosis currently relies on concurrent deficits in muscle mass (ASMI <7.0 kg/m² in males, <5.4 kg/m² in females), grip strength (<26 kg males, <18 kg females), and gait speed (<0.8 m/s), though the Global Leadership Initiative on Sarcopenia (GLIS) now proposes reframing physical performance as an outcome rather than a core diagnostic component.

The review's mechanistic contributions are particularly rich. Five emerging hallmarks of age-related muscle decline are highlighted: chronic low-grade inflammaging, progressive neural dysfunction, extracellular matrix remodeling, diminished vascular perfusion, and disrupted ionic homeostasis. Critically, the authors reframe the role of satellite cells: rather than their depletion being the primary driver of sarcopenia, their dysfunction manifests through impaired paracrine signaling and altered crosstalk with macrophages, fibroblasts, and stromal cells. Mitochondrial dysfunction, including reduced oxidative capacity and increased reactive oxygen species, and neuromuscular junction degeneration — driving a shift from type II to type I fiber predominance — are positioned as pivotal upstream mechanisms. Epigenetic alterations in Polycomb/Trithorax group protein activity further impair myogenic gene expression during regeneration.

On the therapeutic side, the review spotlights several promising frontiers. Stem cell therapy and exosome-based treatments offer regenerative potential by restoring the muscle microenvironment. Altered myokine profiles (muscle-secreted signaling proteins) represent both biomarkers and therapeutic targets. Precision nutrition — moving beyond generic protein supplementation to individualized amino acid and micronutrient strategies — is positioned as a key advancement. The SarQoL® questionnaire is validated as a multidimensional tool for monitoring treatment outcomes across clinical trials, from pharmacological agents like metformin to interventions targeting gut microbiome dysbiosis.

The authors acknowledge that current standard-of-care approaches (resistance exercise and protein supplementation) are constrained by poor long-term adherence and variable individual responses. They call for unified diagnostic standards, point-of-care assessment tools for resource-limited settings, and translational research bridging mechanistic findings to personalized clinical interventions.